Metabolic Syndrome

Underlying Mechanisms and Drug Therapies

Buch | Hardcover

508 Seiten

2011
John Wiley & Sons Inc (Verlag)
978-0-470-34342-5 (ISBN)

Artikel merken

A comprehensive resource, this book offers an overview of the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development. The authors examine the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome.

METABOLIC SYNDROME A comprehensive look at the fight against the metabolic syndrome epidemic

Increasing risk of cardiovascular disease and diabetes, the metabolic syndrome is a world health problem that demands attention from all levels of the health care industry. Metabolic Syndrome: Underlying Mechanisms and Drug therapies extensively covers the metabolic syndrome with an emphasis on drug discovery efforts, providing a context of molecular mechanisms and drug pharmacology for pharmaceutical scientists.

The book starts by examining the physiology of metabolic tissues under normal and disease states, followed by discussions of metabolic diseases and clinical complications. The development of drug therapies based on emerging science is then covered extensively. In addition, there is an in-depth look into the metabolic pathways and dysfunctions in metabolic disease, especially type 2 diabetes and lipid disorders. Finally, a chapter is devoted to past successes and failures in metabolic drug discovery as well as an outlook on future development and challenges.

Divided into four parts, the book:

Addresses important metabolic syndrome basics at the psychological level and metabolic abnormalities at the tissue and pathway levels
Covers the identification of pathways and molecular targets for the development of anti-diabetic therapies
Details pharmaceutical industry approach to solving metabolic and obesity related problems
Describes drug therapies and their limitations and complications, offering a “lessons learned” from existing treatments

With a clear organization and extensive collection of references, the book is a user-friendly and unique tool for scientists in a variety of scientific disciplines in the pharmaceutical and biotechnology industries.

MINGHAN “MING” WANG, PHD is Director and head of a metabolism group in Metabolic Disorders Research at Amgen. He has authored over forty publications and is a regular speaker at drug discovery conferences.

Introduction ix
Minghan Wang

Contributors xi

Part One The Physiology of Metabolic Tissues Under Normal and Disease States

1. Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism 3
Minghan Wang

2. Central Glucose Sensing and Control of Food Intake and Energy Homeostasis 29
Lourdes Mounien and Bernard Thorens

3. Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus 53
Taly Meas and Pierre-Jean Guillausseau

4. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae 73
Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter Zahradka

5. Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis 133
Ruojing Yang

6. Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance 157
Minghan Wang

Part Two Metabolic Diseases and Current Therapies

7. Mechanisms and Complications of Metabolic Syndrome 179
Minghan Wang

8. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL 199
Margrit Schwarz and Jae B. Kim

9. Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery 235
Devan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap

10. Current Antidiabetic Therapies and Mechanisms 253
Minghan Wang

Part Three Drug Targets for Antidiabetic Therapies

11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies 281
Remy Burcelin, Cendrine Cabou, Christophe Magnan, and Pierre Gourdy

12. Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes 327
C.H.S. McIntosh, S.-J. Kim, R.A. Pederson, U. Heiser, and H.-U. Demuth

13. Sodium Glucose Cotransporter 2 Inhibitors 359
Margaret Ryan and Serge A. Jabbour

14. Fibroblast Growth Factor 21 as a Novel Metabolic Regulator 377
Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov

15. Sirtuins as Potential Drug Targets for Metabolic Diseases 391
Qiang Tong

16. 11β-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes 423
Clarence Hale and David J. St. Jean, Jr.

17. Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade 459
Hai Yan, Wei Gu, and Murielle Veniant-Ellison

Part Four Lessons Learned and Future Outlook

18. Drug Development for Metabolic Diseases: Past, Present and Future 471
Minghan Wang

Index 489

Verlagsort	New York
Sprache	englisch
Maße	163 x 241 mm
Gewicht	898 g
Themenwelt	Sachbuch/Ratgeber ► Gesundheit / Leben / Psychologie
	Medizin / Pharmazie ► Medizinische Fachgebiete
	Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie
	Naturwissenschaften ► Chemie
ISBN-10	0-470-34342-7 / 0470343427
ISBN-13	978-0-470-34342-5 / 9780470343425
Zustand	Neuware